Aastrom's heart failure drug enters midstage development

04/8/2013 | Pharmaceutical Business Review Online

Aastrom Biosciences has started recruiting patients for a Phase IIb trial that will assess the safety and efficacy of its experimental drug Ixmyelocel-T in people with advanced heart failure due to ischemic dilated cardiomyopathy. The randomized, double-blind trial will involve 108 patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA